Agennix reports cancer drug Phase II results
The double-blind, placebo-controlled and randomized trial which enrolled 100 patients was designed to assess the efficacy and safety of the talactoferrin in patients with previously treated non-small cell
AtomVie Global Radiopharma has opened a purpose-built radiopharmaceutical manufacturing facility in Hamilton, Ontario, Canada, with an investment of more than $160m.